|
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma 25-Sep-2023 / 23:17 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Berlin, 25 September 2023. Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million. The lutetium-177 supply is conditional to successful validation of Eckert & Ziegler-produced lutetium-177 with the intended compounds. POINT’s pipeline has multiple lutetium-177-based clinical candidates including one candidate for the treatment of metastatic castration-resistant prostate cancer. The agreement’s projected sales volume is based on the successful regulatory approval of a lutetium-177-based clinical candidate in the future. To expand its manufacturing capacities, Eckert & Ziegler plans to invest around € 10 million in its own site in Wilmington, MA. Eckert & Ziegler is thus positioning itself as an important supplier of lutetium-177 in the rapidly growing radioligand therapy market. The strategically significant agreement is expected to start contributing revenues in 2023 and generate substantial earnings if POINT’s clinical candidates receive regulatory approval. The lutetium-177 supply agreement follows a previously signed actinium-225 supply agreement between Eckert & Ziegler and POINT, announced on April 4, 2023. Contact: End of Inside Information 25-Sep-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
AstraZeneca prepares to live with the IRA, shifting focus of arguments to orphan drug changes
NEW YORK — AstraZeneca may be getting ready to live with the Inflation Reduction Act. On Friday morning, CEO Pascal Soriot told reporters that the
November 11, 2023